These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27867016)

  • 1. Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor β 1 and hypoxia dependent repression of GATA-binding factor 3.
    Tu M; Li Z; Liu X; Lv N; Xi C; Lu Z; Wei J; Song G; Chen J; Guo F; Jiang K; Wang S; Gao W; Miao Y
    Cancer Lett; 2017 Mar; 388():187-197. PubMed ID: 27867016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
    Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
    Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2.
    Tu M; Lu C; Lv N; Wei J; Lu Z; Xi C; Chen J; Guo F; Jiang K; Li Q; Wu J; Song G; Wang S; Gao W; Miao Y
    Cancer Lett; 2016 Dec; 383(2):272-281. PubMed ID: 27702660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasohibin-2 promotes proliferation and metastasis of cervical cancer cells by regulating epithelial-mesenchymal transition].
    Wang J; Yu C; Jiang X; Wu X; Jia Y; Zhang H; Li Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jul; 42(7):966-975. PubMed ID: 35869758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway.
    Zhang Y; Xue X; Zhao X; Qin L; Shen Y; Dou H; Sun J; Wang T; Yang DQ
    Cancer Med; 2018 Nov; 7(11):5567-5576. PubMed ID: 30318866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.
    Xue X; Gao W; Sun B; Xu Y; Han B; Wang F; Zhang Y; Sun J; Wei J; Lu Z; Zhu Y; Sato Y; Sekido Y; Miao Y; Kondo Y
    Oncogene; 2013 Mar; 32(13):1724-34. PubMed ID: 22614011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
    Xue X; Zhang Y; Zhi Q; Tu M; Xu Y; Sun J; Wei J; Lu Z; Miao Y; Gao W
    Cell Commun Signal; 2014 Oct; 12():62. PubMed ID: 25269476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HGF and TGFβ1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells.
    Bendinelli P; Maroni P; Matteucci E; Desiderio MA
    Mol Cancer; 2015 Jun; 14():112. PubMed ID: 26041563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRH suppressed TGFβ1-induced Epithelial-Mesenchymal Transition via induction of E-cadherin in breast cancer cells.
    Jin L; Chen J; Li L; Li C; Chen C; Li S
    Cell Signal; 2014 Apr; 26(4):757-65. PubMed ID: 24412750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDA-9/Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor β1 to enhance epithelial-mesenchymal transition in breast cancer.
    Menezes ME; Shen XN; Das SK; Emdad L; Sarkar D; Fisher PB
    Oncotarget; 2016 Dec; 7(49):80175-80189. PubMed ID: 27863394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition.
    Al-Azayzih A; Gao F; Somanath PR
    Biochim Biophys Acta; 2015 May; 1853(5):1229-39. PubMed ID: 25746720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
    Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
    Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expression.
    Tu M; Liu X; Han B; Ge Q; Li Z; Lu Z; Wei J; Song G; Cai B; Lv N; Jiang K; Wang S; Miao Y; Gao W
    Mol Med Rep; 2014 Aug; 10(2):663-9. PubMed ID: 24920244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.
    Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB
    Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia.
    Ren T; Zhang W; Liu X; Zhao H; Zhang J; Zhang J; Li X; Zhang Y; Bu X; Shi M; Yao L; Su J
    J Pathol; 2014 Dec; 234(4):526-37. PubMed ID: 25130389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
    Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
    Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
    Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
    Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
    Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization.
    Sun J; Tu M; Han B; Xue X; Zhang Y; Wei J; Chen J; Lu Z; An Y; Cai B; Lv N; Jiang K; Miao Y; Gao W
    Int J Oncol; 2013 Jul; 43(1):255-61. PubMed ID: 23615928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.